Patent strategy rarely fails loudly. More often, it fails quietlyone missed filing, one deadline slipped by a day, one almost that becomes too late. In a landscape where drug exclusivity is worth billions, even the smallest procedural misstep can cost …

One day late. Nine figures short.
Thats the headline lesson from a recent patent dispute in the pharmaceutical worldone where timing wasnt just important, it was existential. In a market built on years of R&D, regulatory timelines, and blockbuster …

🚨 The most valuable IP insights dont show up in headlines. They show up in footnotes.
In pharma, a Skinny Label opportunity often looks like a rumoruntil it isnt. By the time competitors publicly react, most of the real work has already been done: t…

The myth of the stable drug patent is costing innovators timeand investors money.
For years, the narrative has been comforting: once a drug gets its patent granted, the legal outcome is more or less baked in. In that story, the only volatility is sci…

Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…

Your Paragraph IV strategy isnt failing because the math is hard. Its failing because the market is designed to outmaneuver you.
For years, Paragraph IV filings have been treated like a high-precision weapon: find a vulnerable patent, challenge it, e…

The First-Filers Trap: Why 180-Day Exclusivity Fails Without a Supply-Chain Moat
In the patent universe, speed is power. File first, win firstat least thats the story.
But for generic and biosimilar developers chasing the promise of 180-day exclusivity…

Stop Chasing Blockbusters: The High‑Margin World of Unloved Orphan Drug Patents
Most pharma strategy conversations begin and end with the same word: blockbuster. Big indications, big labels, big targets. Its understandable. But its also increasingly …

Regulatory teams are trained to think in phases: filing windows, protocol alignment, labeling strategy, lifecycle planning. But in todays patent reality, pharma regulatory and patent litigation are collidingand the teams that treat them as separate wor…

Drug discovery loves certaintyespecially at the end of the process, when timelines are collapsing and budgets are locked. But the real tension in pharma isnt technical. Its strategic. And its increasingly legal.
Heres the uncomfortable truth: most pate…